Treatment of Uremic Platelet Dysfunction

Primary Treatment Approach

The American Society of Nephrology recommends desmopressin as the primary pharmacologic treatment for uremic platelet dysfunction, administered at 0.3 μg/kg IV or 3 μg/kg intranasally, with hemostatic effects beginning within 1 hour and lasting 6-8 hours 1, 2
Desmopressin is the evidence-based first-line agent for patients with end-stage renal disease and uremic platelet dysfunction requiring hemostatic intervention 1, 2
The intranasal route of desmopressin is an alternative for home treatment or when IV access is unavailable, with a dose of 3 μg/kg 1, 2

Desmopressin is indicated for active bleeding in uremic patients requiring immediate hemostatic intervention 1, 2
The American College of Critical Care Medicine suggests desmopressin for uremic patients on antiplatelet agents requiring emergent procedures 3

The National Kidney Foundation recommends targeting a hematocrit >25-30% to optimize platelet margination toward vessel walls 4
Adequate dialysis reduces uremic toxin burden that directly impairs platelet function 4
Platelet transfusion is reserved for refractory bleeding unresponsive to desmopressin 3

The European Renal Association notes that desmopressin can cause systemic vasodilation, oliguria, and hypervolemia, requiring careful fluid management 5
The American Heart Association recommends monitoring serum sodium levels, particularly with repeated desmopressin dosing 5

The American Society of Anesthesiologists suggests discontinuing aspirin 5 days before elective procedures when possible 6
The American College of Cardiology recommends discontinuing clopidogrel 7 days before elective procedures when possible 6

The American Society of Hematology recommends doses can be repeated at 12-24 hour intervals for ongoing hemostatic needs, though tachyphylaxis may occur after 3-5 doses due to depletion of endothelial VWF stores 7, 8, 9
The standard subcutaneous dose is 0.3-0.4 μg/kg, which produces therapeutic effects despite the relatively short plasma half-life, as suggested by the European Society of Intensive Care Medicine 10